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Background: Platinum compounds are potent anticancer drugs but also evoke considerable normal tissue damage.
Here, we elucidate the molecular mechanisms contributing to the nephrotoxic effects of cisplatin.
Methods:We comparatively investigated the stress responses of rat kidney tubular (NRK-52E) and glomerular cells
(RGE) following treatmentwith cisplatin (CisPt), oxaliplatin (OxaliPt) and carboplatin (CarboPt). To this end, cell vi-
ability, apoptosis, cell cycle progression, DNAdamage response (DDR) and repair of DNA adductswere investigated.
Results:CisPt reduced the viability of tubularNRK-52E andglomerular RGE cellsmost efﬁciently. Cytotoxicity evoked
by CarboPt occurredwith a delay,whichmight be related to a retarded formation of Pt-(GpG) intrastrand crosslinks.
RGE cells were more sensitive towards all platinum compounds than NRK-52E cells. Platinum drugs efﬁciently
induced caspase-mediated apoptosis in tubular cells, while RGE cells favored G2/M arrest when treated with
equitoxic platinum doses. Mitotic index of NKR-52E and RGE cells was worst affected by OxaliPt. Activation of
the DDR was strikingly agent- and cell type-speciﬁc. Most comprehensive and substantial stimulation of DDR
mechanismswas provoked by CisPt. Repair of Pt-(GpG) intrastrand crosslinks was best in RGE, whichwas reﬂected
by high mRNA expression of nucleotide excision repair (NER) factors.
Conclusions: There are substantial differences regarding the cause of sensitivity and mechanisms of DDR between
tubular and glomerular cells following platinum injury. CisPt is the most potent stimulator of the DDR. We
hypothesize that speciﬁc DNA adducts and thereby forcefully activated pro-toxic DDR mechanisms contribute to
the exceptionally high acute nephrotoxicity of CisPt.© 2015 Elsevier B.V. All rights reserved.langiectasia mutated; ATR, ATM
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Platinum compounds are highly potent anticancer drugs and
widely used in the therapy of malignant diseases. For instance,
cisplatin (cis-diamminedichloroplatinum(II); CisPt), which is the ﬁrst
platinum compound that has been used for anticancer therapy [1],
is preferential for the therapy of various types of cancer, including
head and neck, lung, ovarian, cervical, bladder, and testicular cancer
[2]. CisPt enters the cell by passive diffusion and by transporters
[3–7]. Upon uptake into the cell, its chloride ligands are replaced
by water leading to the formation of an electrophilic intermediate
that can induce DNA adducts by SN2-like mechanism [2]. Apart
from DNA monoadducts and DNA interstrand crosslinks, DNA
intrastrand crosslinks (GpG and ApG) are the most abundant adducts
formed by CisPt [8,9]. In particular themajor GpG intrastrand crosslinks
cause a substantial distortion of the DNA double helix [10,11],
which results in a block of transcription and replication [12,13], thereby
inducing cell death [14]. Carboplatin (cis-diammine-1,1-cyclobutane-
686 K. Krüger et al. / Biochimica et Biophysica Acta 1853 (2015) 685–698dicarboxylatoplatinum (II); CarboPt) and oxaliplatin (trans-L-1,2-
diaminocyclohexane-oxalatoplatinum(II); OxaliPt) are two other
types of platinum compounds. Whereas CarboPt has the same
spectrum of antitumor activity as CisPt, OxaliPt demonstrates
antitumor efﬁcacy against CisPt resistant tumors, notably colorectal
cancer [2]. This might be due to a different mode of action of CisPt,
OxaliPt and CarboPt [15,16]. It is also conceivable that (i) mechanisms
of transport, (ii) the molecular structure of cytotoxic DNA adducts,
(iii) pro-apoptotic DNA damage response (DDR), (iv) the repair of
primary or secondary DNA lesions and/or (v) the activation of DNA
damage independent cell death pathways or survival mechanisms are
of relevance for the differences in response of tumor cells to platinating
drugs. Correspondingly, numerousmechanisms have been suggested to
be involved in the resistance of tumor cells to platinum compounds [17,
18]. A major mechanism involved in the removal of CisPt-induced
intrastrand crosslinks is nucleotide excision repair (NER) [19,20],
including transcription-coupled nucleotide excision repair (TC-NER)
[21]. The relevance of DNA repair for platinum susceptibility is
highlighted by the fact that the expression of ERCC1, which is involved
in nucleotide excision repair (NER), predicts the therapeutic efﬁcacy of
CisPt in lung and testis tumors [22–27]. Apart from NER, mismatch
repair (MMR) has been suggested to be important for the speciﬁc
detection of CisPt DNA adducts but not of DNA adducts generated by
OxaliPt [28].
The clinical use of platinum compounds is limited by numerous
adverse effects on normal tissue. The clinically most relevant
dose-limiting adverse effect of CisPt is nephrotoxicity [29], while
hematotoxicity (i.e. myelosuppression) and neurotoxicity (peripheral
neuropathy) are the dose limiting side effects of CarboPt and OxaliPt,
respectively [15,30]. The molecular mechanisms underlying the
tissue-speciﬁc adverse effects of the various platinating drugs are largely
unclear. One possible explanation for the preferential cytotoxic effect of
CisPt to the kidney are platinum drug-speciﬁc transporters. Although
CisPt and OxaliPt share some major transporters, they also have
compound-speciﬁc ones [4,31–33]. However, other mechanisms such as
the formation of particular types of DNA lesions, activation of different
branches of the DDR and/or pro-apoptoticmechanisms aswell as varying
capacities to repair CisPt-, OxaliPt- or CarboPt-inducedDNA lesionsmight
be of relevance as well. The severity of CisPt-induced peripheral neuro-
toxicity has been related to insufﬁcient DNA repair [34]. CisPt-induced
nephrotoxicity is believed to mainly result from damage to tubular cells
[29,35], with the formation of ROS [36], ATR-Chk2 signaling [37] and
mechanisms of transport [4,38] being suggested to play pivotal roles. Cor-
respondingly, prevention of ROS formation [39,40] and stimulation of
anitoxidative mechanisms by targeting of Nrf2 signaling [41] or
inhibition of inﬂux transporters [42] have been considered as
nephroprotective strategies. Noteworthy, glomeruli are further particu-
larly sensitive structures of the kidney, which are especially relevant
for nephrotoxicity induced by aminoglycosides or cyclosporin [43,44]
and, furthermore, play a key role in autoimmune glomerulonephritis
[45,46]. Thus, it was speculated that damage to glomeruli provoked by
CisPt might also contribute to the renal toxicity of this anticancer drug
[47].
In the present study we addressed the question whether various
types of renal cells show qualitative and quantitative differences
regarding their responsiveness to platinum injury. To this end, we
comparatively analyzed the response of normal rat renal tubular
epithelial (NRK-52E) and glomerular endothelial (RGE) cells to treat-
ment with equitoxic concentrations of CisPt, OxaliPt and CarboPt,
monitoring the activation of cell cycle checkpoints, induction of
apoptotic mechanisms, stimulation of mechanisms of the DDR as well
as the formation and repair of DNA intrastrand crosslinks and DNA
double-strand breaks (DSBs). The results of our extensive studies reveal
strikingly complex differences in the stress responses stimulated by
the different platinum compounds in tubular epithelial and glomerular
endothelial cells.2. Materials and methods
2.1. Materials
Rat renal proximal tubular epithelial (NRK-52E) and rat glomerular
endothelial (RGE) cells originate from the German Collection of
Microorgansisms and Cell Culture (DSMZ) (Braunschweig, Germany).
Cisplatin, oxaliplatin and carboplatin were obtained from the pharma-
ceutical department of the University Hospital Düsseldorf and originate
from TEVA (Ulm, Germany). The following antibodies were used:
antibody detecting Ser139 phosphorylated histone H2AX (γH2AX)
(Millipore (Billerica, USA)), ERK2, PARP-1, CENP-F andβ-actin antibodies
(Santa Cruz Biotechnology (Santa Cruz, USA)), p-p53, p-Chk1, caspase 3
(additionally detects cleaved caspase 3), caspase 7 and cleaved caspase
7 (Cell Signaling (Denvers, Massachusetts, USA)), p-Chk2 and Ki-67
(Abcam (Cambridge, England)), p-RPA32 and p-Kap-1 (Bethyl
Laboratories (Montgomery, USA)), GAPDH and p-c-Jun (Epitomics (Bur-
lingame, USA)). The antibody against Pt-(GpG) intrastrand crosslinks
was kindly provided by J. Thomale (Essen, Germany). The antibody de-
tecting S10-phosphorylated histone 3 (p-H3) is part of the “HCS Mitotic
Index Kit” (Life Technologies, Carlsbad, CA, USA). The ﬂuorescent anti-
body Alexa Fluor 488 was obtained from Life Technologies (Carlsbad,
CA, USA), and the horseradish peroxidase-conjugated antibodies anti-rat
IgG, anti-mouse IgG, anti-rat IgG and anti-rabbit IgG were purchased
from Rockland (Gilbertsville, PA, USA).
2.2. Cell culture
NRK-52E cells were grown in DMEM (Sigma, Steinheim, Germany),
RGE cells in RPMI (Sigma, Steinheim, Germany) containing 10% of
fetal calf serum (FCS) (PAA Labratories, Cölbe, Germany; Biochrom,
Berlin, Germany) and 1% penicillin/streptomycin (Sigma, Steinheim,
Germany) at 37 °C in an atmosphere containing 5% CO2. If not stated
otherwise, treatment of logarithmically growing cells was performed
24 h after seeding. Ionizing radiation was performed with a caesium-
137 radiation source.
2.3. Determination of cell viability
Cell viability was determined using the MTT assay [48]. Brieﬂy,
the yellow tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (Sigma, Steinheim, Germany) is metabolized to a
purple formazan dye by mitochondrial dehydrogenases, which are
only active in living cells. Untreated control and platinum-treated cells
were incubated with the tetrazolium salt (5 mg/ml in PBS) for 30–
40 min at 37 °C. Afterwards the dye was solubilized with DMSO
(MERCK, Darmstadt, Germany) and absorption was measured at
560 nm. Relative viability in the untreated controls was set to 100%. In
addition, cell viability was also determined by use of the Alamar Blue
assay [49]. Here, viable cells metabolize the non-ﬂuorescent dye
resazurin (Sigma, Steinheim, Germany) to ﬂuorescent resoruﬁn. The
cells were incubated for up to 2.5 h with the resazurin solution (ﬁnal
concentration 40 μM) before ﬂuorescence was measured (excitation:
535 nm, emission: 590 nm, 5 ﬂashes, integration time: 20 μs). Relative
viability in the untreated controls was set to 100%. Additionally,
alteration in cell viability was recorded in real-time by measuring the
electrical impedance via the iCElligence system (ACEA Bioscience, San
Diego, USA). 200 μl mediumwas added to the E-Plate L8 for background
measurements. Subsequently, cells were seeded in additional 250 μl
medium. Appropriate cell densities were determined by preliminary
experiments. Cell attachment was monitored by measuring the imped-
ance for 4 h (240 sweeps; time interval: 1 min). Afterwards impedance
was recorded over a time period of 72 h (192 sweeps; time interval
30 min). 24 h after seeding, cells were treated with the platinating
drugs by adding the corresponding concentrations in 50 μl medium.
Changes in the electrical impedance were expressed as cell index
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the Trypan Blue exclusion assay. In this assay, living cells with intact
membranes exclude the dye,whereas dead cells do not. For the analysis,
cells were treated with the platinum compounds 24 h after seeding.
After further incubation period of 24–72 h cells were trypsinized,
washed with PBS and suspended 5:1 in 0.4% Trypan Blue solution
(Sigma, Steinheim, Germany). After incubation for 1 min at RT the
number of Trypan Blue negative (=viable) cells was counted micro-
scopically using a Neubauer chamber.
2.4. Flow cytometry-based analysis of cell cycle distribution and cell death
Cell cycle distribution was analyzed by ﬂow cytometry. To this end,
cells were trypsinized, washed and resuspended in PBS. Afterwards
they were ﬁxed with ice-cold ethanol (−20 °C, ≥20 min). After centri-
fugation (800 × g, 5 min, 4 °C) the supernatant was discarded. The cells
were resuspended in PBS containing RNase A (Serva Electrophoresis
GmbH, Heidelberg, Germany) (1 μg/μl) and were incubated for 1 h at
RT. After adding propidium iodide (Sigma, Steinheim, Germany) the
cells were subjected to ﬂow cytometric analysis (Becton Dickinson,
Heidelberg, Germany) for quantiﬁcation of the percentage of cells
present in G0/G1 and G2/M-phase of the cell cycle. The SubG1 fraction
was considered as a measure of dead (apoptotic) cells.
2.5. Analysis of cell cycle progression by immunocytochemistry
Apart from ﬂow cytometry-based analyses, alterations in cell cycle
progression were monitored by determination of the mitotic index
via immunocytochemical detection of S10 phosphorylated histone 3
(p-H3). Furthermore, the percentage of cells expressing the centromer
speciﬁc protein CENP-F and the proliferation marker Ki-67 was quanti-
ﬁed. For all immunocytochemical analyses, the cells were seeded onto
cover slides. After treatment cells were ﬁxed with 4% formaldehyde in
PBS (MERCK, Darmstadt, Germany) (15 min; RT) and incubated with
ice-cold methanol (20 min;−20 °C). After blocking (1 h; RT; blocking
solution: 5% BSA (Calbiochem) in PBS containing 0.3% Triton X-100
(Sigma, Steinheim, Germany)) incubation with p-H3 (1:50), Ki-67
(1:750) or CENP-F (1:100) antibodies was performed over night at
4 °C. After washing, the secondary ﬂuorescent-labeled antibody was
added (1:500; 2 h; RT; in the dark). The cells were mounted in
Vectashield (Vector Laboratories) containing the nuclear dye DAPI.
Microscopical analysis was performed using an Olympus BX43 ﬂuores-
cencemicroscope. Toﬁgure out the effects of platinum treatment on the
number of S-phase cells, the incorporation of EdU was measured using
the “EdU-Click 488” Kit (PANATecs GmbH, Heilbronn, Germany). After
EdU pulse (30 min), untreated and platinum-treated cells were ﬁxed
as described above. After blocking (2 × 5 min; RT; blocking solution:
3% BSA (Calbiochem) in PBS) the cells were permeabilised with PBS
containing 0.3% Triton X-100 (Sigma, Steinheim, Germany) (20 min,
RT) followed by incubation for 1 h at RT in the dark according to the
manufacturer's protocol. Cells were mounted as described above and
the percentage of EdU positive cells was counted by ﬂuorescence
microscopy.
2.6. Apo-ONE® assay
For analyzing the activation of caspases 3 and 7 the “Apo-ONE®
homogeneous Caspase-3/7 Assay Kit” (Promega, Madison, Wisconsin,
USA) was used according to the manufacturer's protocol. In this assay,
the proﬂuorescent caspase 3 and 7 substrate rhodamine 110 (bis-(N-
CBZ-L-aspartyl-L-glutamyl-L-valyl-L-apartic acid amide; Z-DEVD-R110)
is sequentially cleaved by caspase 3 and 7, releasing the ﬂuorescent
dye rhodamine 110. Before performing the Apo-ONE® assay, cell
viability was determined via the aforementioned Alamar Blue assay.
Afterwards, 50 μl of the Apo-ONE®substratewas added to 50 μl residual
medium and the increase of ﬂuorescence (ΔRFU) was measured over3 h at 37 °C (excitation: 499 nm; emission maximum: 521 nm). The
increase of ﬂuorescence over time reﬂects the activity of the caspases
3 and 7. ΔRFU was normalized to cell viability as well as to untreated
control.
2.7. Analysis of DNA damage induction and DNA repair
The amount of DNA double-strand breaks (DSBs) was quantiﬁed by
measuring the level of S139 phosphorylated H2AX (γH2AX), which is a
surrogatemarker of DNAdamage [50,51], byWestern blot analysis or by
immunocytochemistry-based analysis of nuclear γH2AX foci. For
immunocytochemical analysis, the cells were seeded onto cover slides.
After treatment the cells were ﬁxed with 4% formaldehyde in PBS
(MERCK, Darmstadt, Germany) (15 min; RT) and incubated with
ice-cold methanol (overnight; −20 °C). After blocking (1 h; RT;
blocking solution: 5% BSA (Calbiochem) in PBS/0.3% Triton X-100
(Sigma, Steinheim, Germany)), incubation with γH2AX antibody was
performed (1:500; over night; 4 °C). Afterwashingwith PBS/0.3% Triton
X-100, the secondary ﬂuorescence-labeled antibody was added (1:500;
2 h; RT; in the dark). The cells were mounted in Vectashield (Vector
Laboratories) containing DAPI. Microscopical analysis was performed
using an Olympus BX43 ﬂuorescence microscope.
2.8. Western blot analyses
The level of protein expression was determined by Western blot
analysis. Total cell extracts were obtained by lysing an equal number
of cells in Roti®-Load buffer (Carl Roth GmbH, Karlsruhe, Germany)
(5 min; RT). After sonication (EpiShear™ Probe sonicator, active motif,
La Hulpe, Belgium) proteins were denatured by heating (5 min; 95 °C)
and separated by SDS-PAGE (12.5% gel). Subsequently, proteins were
transferred onto a nitrocellulose membrane (GE Healthcare, Little
Chalfont, UK) via the Protean Mini Cell System (BioRad, München,
Germany). After blocking in 5% non-fat milk in TBS/0.1% Tween 20
(MERCK, Darmstadt, Germany), (2 h; RT), themembranewas incubated
with the corresponding primary antibody (1:1000; over night; 4 °C).
After washing with TBS/0.1% Tween 20 the secondary (peroxidase-
conjugated) antibody was added (1:2000; 2 h; RT). For visualization
of the bound antibodies the Fusion FX7 imaging system (Pequlab,
Erlangen; Germany) was used.
2.9. Quantitative real-time PCR-based mRNA expression analyses
Total RNAwas puriﬁedbyusing theRNeasyMini Kit (Qiagen,Hilden,
Germany). The reverse transcriptase (RT) reaction was performed by
use of the OmniScript Kit (Qiagen) with 1000 ng of mRNA. For each
PCR reaction 40 ng of cDNA and 0.25 μM of the corresponding primers
(Euroﬁns MWG Synthesis GmbH, Ebersberg, Germany) were used.
Quantitative real-time PCR analysis was performed in duplicates by
using the QPCR-SYBR Green Fluorescein Mix (Thermo Fisher, Dreieich,
Germany) and a CFX96 Real-Time System (BioRad, Munich, Germany)
with the Bio-Rad CFX Manager 3.1 software. PCR runs were done as
follows: 1. 95 °C, 2 min; 2. 95 °C, 30 s—60 °C, 30 s—72 °C, 40 s;
3. 72 °C, 10 min. At the end of the runs, melting curves were analyzed
to ensure the speciﬁcity of the ampliﬁcation reaction. The following
primers were used: Bax, f: TCATGAAGACAGGGGCCTTT, r: CTGCAGCT
CCATGTTGTTGT; Bcl2, f: CTTCAGGGATGGGGTGAACT, r: CAGCCTCCGT
TATCCTGGAT; Ercc1, f: GAAGCCTGCTGACCTCCTTA, r: GATGCGGTGATG
AGCTGTTC; Xiap, f: AGAAGCCAGACTGAAGACGT, r: AGTGTCTCCTGTGC
TCTGAC; Ctr1, f: TATTTGGTGGCTGGGGTTCT, r: CACTAGGTCTGGAGAG
GCAC;Mrp2, f: GGAGCTGGTTGGAAACTTGG, r: TTGGTCTCTGCTTCTGAC
GT; Xpa, f: TCGATTTGCCAACATGCGAT, r: ATGGCGAGGGTTCTTCTTCA;
Xpg, f: CCTGGACAAAGCAAACGGAA, r: GAACCTTCTGCCTCCTCACT; Csb,
f: AGTGTGGTCTGGATGGGAAG, r: ATGGAGTGGAGCGGACTATG; Gapdh,
f: GTATGACTCTACCCACGGCA, r: AAGACGCCAGTAGACTCCAC; β-actin,
f: GGGAAATCGTGCGTGACATT, r: CAGGAAGGAAGGCTGGAAGA. mRNA
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otherwise, relative mRNA expression of untreated control cells was set
to 1.0.
2.10. Analysis of cellular platination
For measuring overall cellular platination, cells were treated for 4 h
with the IC80 of the corresponding platinum drugs before they were
ﬁxed with 75% of HNO3 and scraped off. Afterwards the cells were
heated (2 h; 65 °C) and stored at 4 °C until measurement. The platinum
level in the cells was measured via an ICP-MS spectrometer (Thermo
Finnigan, Bremen, Germany) as described [52].
2.11. Analysis of platinum-induced DNA intrastrand crosslinks
The level of Pt-(GpG) intrastrand crosslinks was monitored by
Southwestern blot analysis as well as by immunocytochemistry. For
the Southwestern blot analysis genomic DNA was isolated using the
“DNeasy Blood and Tissue” kit (Qiagen, Hilden, Germany). The concen-
tration and purity of the DNA were measured photometrically
(NanoVueTMPlus (GE Healthcare, UK)) and were conﬁrmed by agarose
gel electrophoresis. 0.5 μg of the DNA was diluted with TE buffer up
to 100 μl, denatured by heating (10 min, 95 °C) and cooled on ice.
Afterwards, 100 μl ice cold ammonium acetate (2 M) was added. A
nitrocellulose membrane was soaked in 1 M ammonium acetate and
put into the slot-blot apparatus (Roth, Karlsruhe, Germany). The DNA
was transferred onto the membrane by using a vacuum pump. After
washing with 1 M ammonium acetate and water, the membrane was
incubated with 5 × SSC (10 × SSC: 1.5 M NaCl, 150 mM sodium citrate,
pH 7.0) for 5 min before it was blocked in 5% non-fat milk in TBS/0.1%
Tween 20 overnight at 4 °C. Incubation with the primary antibody
directed against Pt-(GpG) intrastrand crosslinks (1:200) [53] was
conducted for 1 h at RT, followed by incubation with peroxidase-
conjugated anti-rat IgG secondary antibody (1:2000, 2 h, RT).
Visualization of the Pt-(GpG) intrastrand crosslinks was done by
chemiluminescence. Autoradiographies were densitometrically ana-
lyzed. Additionally, the membrane was stained with methylene blue
to ensure equal DNA loading. For immunocytochemistry-based detec-
tion of Pt-(GpG) crosslinks cells were trypsinized, counted and washed
twice with PBS. A drop of 10 μl of the cell suspension (1 × 106 cells/ml
PBS) was placed onto Superfrost® Plus Gold slides (Thermo Scientiﬁc).
The cells were dried on air and stored at −20 °C until analysis.
Antibody-based detection of DNA intrastrand crosslinks was performed
as described [53].
2.12. Statistical analysis
For statistical analysis the unpaired two-tailed Student's t-test was
applied. p-Values ≤0.05 were considered as signiﬁcant.
3. Results
3.1. Cytotoxic effects of platinating drugs on normal rat kidney cells
In order to analyze the sensitivity of rat proximal tubular epithelial
NRK-52E and glomerular endothelial RGE cells to various platinum
compounds (cisplatin, oxaliplatin and carboplatin), the viability of the
cells was analyzed 72 h after drug addition employing the MTT assay.
NRK-52E and RGE cells were most sensitive to cisplatin (CisPt)
(Fig. 1A and 1B), with RGE cells showing a higher sensitivity than
NRK-52E cells. The IC50 for CisPt was 10 μM and 5 μM for NRK-52E
andRGE cells, respectively (Fig. 1A andB, Table 1). Regarding oxaliplatin
(OxaliPt), the IC50 was 5 μM for both cell lines (Fig. 1A and B, Table 1).
Concerning carboplatin (CarboPt), RGE cells were more sensitive than
NRK-52E cells with IC50 of 100 μM and 22 μM for NRK-52E and RGE,
respectively (Fig. 1A and B, Table 1). If calculating the IC80, a highersusceptibility of RGE cells was observed for all platinum compounds
(Table 1). Cell viability was also analyzed 24 h after drug addition,
again showing the highest sensitivity towards CisPt and for RGE cells
(Supplementary Fig. S1A, Supplementary Table 1). Taken together, the
in vitro data show that glomerular cells are more sensitive to the inhib-
itory effects of platinating drugs, including the especially nephrotoxic
compound CisPt, on cell viability than tubular cells. Analyzing the time
kinetic of cytotoxicity following platinum treatment, real-time analyses
of electrical impedance were employed. The onset of cytotoxicity
following CisPt and OxaliPt treatment with the corresponding IC80
was observed ~10–12 h after drug addition (Fig. 1C). By contrast,
cytotoxicity resulting from exposure to CarboPt occured with a clear
time delay and started ~24–36 h after treatment in both types of kidney
cells (Fig. 1C). In addition, the number of viable cells was determined
using theTrypanBlue exclusion assay. As observed24h (Supplementary
Fig. S1B) and 72 h (Fig. 1D) after treatment, nomajor differences in the
number of residual viable cells were observed between tubular epithe-
lial and glomerular endothelial cells using this assay. This indicates that
the enhanced sensitivity of the RGE cells, as observed in the MTT assay,
predominantly results from a loss of cell viability,which is reﬂected by a
decrease in mitochondrial activity, rather than the induction of cell
death.3.2. Platinum compounds differently affect cell cycle progression of normal
rat kidney cells
The impact of platinating agents on cell cycle progression was
analyzed by ﬂow cytometry. Treatment of NRK-52E cells with the IC50
of CisPt caused an increase in the Sub-G1 fraction, which represents
the apoptotic population, already 24 h after treatment (Fig. 2A, Fig. 2B
and Supplementary Fig. S2A). This pro-apoptotic effect was stronger
when the IC80 of CisPt was used (Fig. 2A, Fig. 2B and Supplementary
Fig. S2A). CarboPt and OxaliPt were less efﬁcient in driving cells into
apoptosis (Fig. 2A, Fig. 2B and Supplementary Fig. S2A). Strikingly, treat-
ment of RGE cells with CisPt did not cause any increase in SubG1 phase
cells, neither 24 h nor 48 h after exposure to the IC50 or IC80 (Fig. 2C,
Fig. 2D and Supplementary Fig. S2A and B). Rather, RGE cells responded
to treatmentwith the IC50 of CisPtwith aG2/M arrest both 24 h and 48 h
after exposure (Fig. 2C, Fig. 2D and Supplementary Fig. S2C and D). G2/
M arrest was also observed 48 h after treatment of RGE with the IC80 of
OxaliPt and CarboPt (Fig. 2C, Fig. 2D and Supplementary Fig. S2C and D).
To further elucidate the inﬂuence of the platinum drugs on cell cycle
progression, mitotic index was determined by immunocytochemical
detection of phospho-histone (p-H3) positive cells. 24 h after OxaliPt
treatment of NRK-52E cells the percentage of p-H3 expressing cells
has decreased by about 80% (Fig. 3A). Equitoxic doses of CarboPt
showed only minor effects (Fig. 3A). As compared to OxaliPt
and CarboPt, CisPt caused an intermediate decrease in the percentage of
p-H3 positive tubular cells (Fig. 3A). OxaliPt was also most efﬁcient in
reducing the frequency of p-H3 positive glomerular cells (Fig. 3C). The
number of cells expressing centromere speciﬁc protein CENP-F was
signiﬁcantly increased following CisPt, OxaliPt and CarboPt treatment
ofNRK-52E cells,while RGE cells did not show this response (Supplemen-
tary Fig. S3A and B). S-phase activity of treated cells was monitored by
measuring the incorporation of EdU. Regarding NRK-52E cells, a signiﬁ-
cant decrease in EdU positivity was observed following treatment with
OxaliPt (Fig. 3B). By contrast, RGE cells revealed a minor reduction in
EdU incorporation following CisPt treatment, while the percentage of
EdU positive cells was slightly increased after OxaliPt and CarboPt treat-
ment (Fig. 3D). Measuring the number of Ki-67 positive cells, only CisPt
treatment of NRK-52E cells resulted in a slight decrease (Supplementary
Fig. S3C and D). Taken together, the data show that equitoxic
concentations (i.e. IC80) of various platinating anticancer drugs largely dif-
fer from each other with respect to the activation of G2/M and S-phase
checkpoint mechanisms in tubular and glomerular cells.
Fig. 1. Tubular (NRK-52E) and glomerular (RGE) cells differ in their sensitivity to platinum compounds. A, B: Logarithmically growingnormal rat tubular epithelial cells (NRK-52E) (A) and
glomerular endothelial cells (RGE) (B) were incubated with different concentrations of the platinum compounds for 72 h. Cell viability was measured using the MTT assay as described
in methods. Results are expressed as viable cells in percent of the untreated control, which was set to 100%. Data shown are the mean ± SD from 3 to 5 independent experiments
each performed in quadruplicate. *: signiﬁcance of CisPt vs. OxaliPt; #: signiﬁcance of CisPt vs. CarboPt; +: signiﬁcance of OxaliPt vs. CarboPt. ***, ###, +++p ≤ 0.001; ++p ≤ 0.01.
C: NRK-52E and RGE cells were treated with the corresponding IC80 of the different platinum compounds. Cell growth was measured by recording alterations in electrical impedance
in real-time as described in methods. Shown are data from one representative experiment. Con, untreated control. D: Logarithmically growing rat tubular epithelial (NRK-52E) and
glomerular endothelial (RGE) cells were incubated with the IC50 of the platinum compounds for 72 h. The number of viable cells was determined by Trypan Blue exclusion assay as
described inmethods. The number of viable (i.e. Trypan Blue negative) cells at the time of drug addition (Con2) was set to 100%. Data shown are the mean± SD from one representative
experiment performed in triplicate. Con1, untreated control after incubation period of 72 h; Con2, untreated control at the time of platinum treatment; CisPt, OxaliPt, CarboPt, percent
viable cells 72 h after platinum treatment.
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kidney cells
Next, we analyzed the inﬂuence of equitoxic concentrations of
platinating agents on apoptotic cell death using the Apo-ONE® assay,Table 1
Inﬂuence of platinating drugs on the viability of normal rat kidney cells.
Shown are the IC50 and IC80 of rat kidney tubular epithelial (NRK-52E) and glomerular
endothelial (RGE) cells treated for 72 h with different types of platinating drugs. Shown
are the mean values ± SD from 3 to 5 independent experiments each performed in
quadruplicate.
MTT NRK-52E RGE
IC50 IC80 IC50 IC80
CisPt 10 ± 1.5 μM 32 ± 8.1 μM 5 ± 1.7 μM 14 ± 4.2 μM
OxaliPt 5 ± 1.6 μM 133 ± 9.9 μM 5 ± 1.1 μM 30 ± 13.4 μM
CarboPt 100 ± 12.9 μM 179 ± 9.5 μM 22 ± 7.4 μM 63 ± 7.4 μMwhich measures the activation of executor caspase 3 and 7. Among
the various platinum compounds tested, IC80 of CisPt and OxaliPt
revealed the most profound (i.e. ~40–50-fold) activation of executor
caspases 24 h after treatment of NRK-52E cells (Fig. 4A). Stimulation
of caspase activity following platinum treatment of RGE cells was rather
weak as compared to NRK-52E (Fig. 4A). At later time point (i.e. 72 h
after drug addition), highest level of caspase activity was detected in
CarboPt treated NRK-52E (Fig. 4B). Western blot analysis revealed
high levels of cleaved caspase 3 and 7 in NRK-52E cells 24 h after treat-
mentwith IC80 of CisPt (Fig. 4C). Noteworthy, OxaliPt caused cleavage of
caspase 7 only and CarboPt treatment did not increase protein levels of
cleaved caspases (Fig. 4C). Regarding RGE cells, a substantial increase in
the levels of cleaved caspases 3 and 7 was found 24 h after treatment
with the IC50 of CisPt and OxaliPt and 72 h after exposure to CisPt
(Fig. 4D). These data support the note of surprisingly agent- and cell
type-speciﬁc apoptotic responses induced by equitoxic doses of various
platinating drugs.
Fig. 2.Effect of platinumcompounds on cell cycle distribution is cell type-speciﬁc. NRK-52E (A, B) and RGE (C, D) cellswere incubatedwith the IC50 and IC80 of the platinumcompounds for
24 h or 48 h followed by analysis of cell cycle distribution by ﬂow cytometry. A, C: Representative results of NRK-52E (A) and RGE (C) cells. Con, untreated control. B, D: Mean values
obtained from at least two independent experiments each performed in duplicate. B, NRK-52E cells; D, RGE cells. Con, untreated control.
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platinating drugs in normal rat kidney cells
Cells respond to the formation of DNAdamagewith the so-calledDNA
damage response (DDR), which regulates DNA repair, cell cycle progres-
sion anddeath. ThePI-3-like kinasesATM,ATRandDNA-PKcs are key reg-
ulators of the DDR [54–56]. In the course of the DDR histone H2AX is
phosphorylated at Ser139 by the aforementioned kinases. Therefore,
S139 phosporylated H2AX (γH2AX) is a prototypical marker of the
DDR, which is efﬁciently activated by DNA double-strand breaks (DSBs)[50,51,57]. Assaying the formation and disappearance of nuclear γH2AX
foci, which reﬂect DSBs, all platinating drugs slightly increased the num-
ber of foci 8 h after treatment of NRK-52E with the IC50 and IC80
(Fig. 5A). A more substantial formation of DSBs was observed after 8 h
of pulse-treatment with the IC80 followed by a post-incubation period of
24 h (Fig. 5A). Here, CisPt was only slightly more efﬁcient than OxaliPt
and CarboPt. As compared to tubular NRK-52E cells, glomerular RGE
cells responded with an increased number of γH2AX foci already 8 h
after platinum treatment (Fig. 5C). After post-incubation period of 24 h,
a substantial increase in the number ofγH2AX fociwas detectable already
Fig. 3. Agent-speciﬁc effects of platinum drugs onmitotic progression and S-phase activity. A, C: NRK-52E (A) and RGE (C) cells were incubated with the IC80 of the platinum compounds
(CisPt, OxaliPt, CarboPt) for 24h. Afterwards the frequency of phospho-histoneH3 (p-H3) positive cellswasmeasured by immunocytochemistry. Data shown are themean±SD from two
independent experiments each performed in duplicate. *p ≤ 0.05; **p ≤ 0.01. The percentage of centromere protein F (CENP-F) expressing cells is shown in Supplementary Fig. S3. Con,
untreated control. B, D: NRK-52E (B) and RGE (D) cells were incubated with the IC80 of the platinum compounds for 24 h. Afterwards cells were pulse-labeled with EdU as described in
methods and EdU incorporation was evaluated by ﬂuorescence microscopy. Data shown are the mean ± SD of two independent experiments each performed in duplicate. *p ≤ 0.05;
**p ≤ 0.01; ***p ≤ 0.001. The percentage of centromere protein Ki-67 positive cells is shown in Supplementary Fig. S3. Con, untreated control.
Fig. 4. Activation of caspases by platinum compounds. NRK-52E (A, C) and RGE cells (B, D) were incubated with the IC50 and IC80 of the platinum compounds (CisPt, OxaliPt, CarboPt) for
24h or 72 h followedby the analysis of caspase activity using theApo-ONE®assay as described inmethods (A, B). Additionally, the level of cleaved procaspases 3 and 7 and cleavedPARP-1
protein was determined byWestern blot analysis (C, D). Quantitative data shown in A and B are the mean± SD from at least two independent experiments each performed in triplicate.
Con, untreated control.
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Fig. 5. Induction of DNA double-strand breaks (DSBs) and activation of the DDR in normal rat kidney cells by platinumdrugs. NRK-52E (A, B) and RGE (C, D) cells were incubatedwith IC50
and IC80 of the platinum compounds (CisPt, OxaliPt or CarboPt) for 8 h, whichwas followed or not by a subsequent post-incubation period of 24 h (8 h+ 24 h) in the absence of platinum
drugs. A, C: The amount of DNA double-strand breaks (DSBs)was quantiﬁedbymeasuring thenumber of nuclearγH2AX foci by immunocytochemistry. Theupper part of theﬁgure shows
representative pictures. The quantitative results shown in the lower panel display the number of γH2AX foci per cell (mean ± SD) of≥2 independent experiments. For each experiment
≥50 nuclei were counted. Con, untreated control. B, D: Activation status of mechanisms of the DNA damage response was analyzed by Western blot analysis using a panel of phospho-
speciﬁc antibodies as indicated. For protein loading control, the expression of ERK2, GAPDH and β-actin was investigated. Data are summarized in Table 2. Con, untreated control.
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ences in the formation of γH2AX foci after exposure of NRK-52E and RGE
to platinating agents indicate that both cell types differ from each regard-
ing the formation of DSBs and related DDR. Notably, the response to ion-
izing radiation was similar in both cell types (Supplementary Fig. S4),
showing that the differences observed are speciﬁc for platinum com-
pounds. To scrutinize the hypothesis that activation of DDR by platinating
agents occurs in an agent- and cell type-speciﬁcmanner, extensiveWest-
ern blot analyses were performed. The results obtained point to a highly
complex spectrum of different responses (Fig. 5B and D). For instance,
IC80 of CisPt and OxaliPt stimulated a strong phosphorylation of p53 and
Chk1 following 8 h after treatment of NRK-52E, whereas no clear activa-
tion of Chk2, RPA32 or Kap-1 was found (Fig. 5B). CarboPt stimulated aselective increase in the level of p-Chk1 protein but not of p-p53. Follow-
ing a post-incubation period of 24 h, all three platinating drugs triggered
clear phosphorylation of Chk2, RPA32 and Kap1 in both tubular and glo-
merular cells, with CarboPt being the most potent inducer of Chk2
(Fig. 5B). Glomerular cells revealed a stronger activation of Chk1 as com-
pared to tubular cells (Fig. 5B and D). In extension of these analyses, DDR
was further analyzed after continuous treatment with CisPt, OxaliPt and
CarboPt for 24 h and 48 h. The results obtained conﬁrm the note of sub-
stantial differences in the activation of the DDR, as reﬂected by the phos-
phorylation of H2AX, p53, Chk1, Chk2 and Kap1, by different platinum
drugs in different renal cell types (Fig. 6A and B). The complex cell type-
and agent-speciﬁc variations observed in platinum-induced DDR in
NRK-52E and RGE are summarized in Table 2.
Fig. 6.Qualitative and quantitative differences in platinum-induced activation of the DDR in tubular NRK-52E and glomerular RGE cells. NRK-52E and RGE cells were treatedwith the IC50
and IC80 of the corresponding platinum compounds (CisPt, OxaliPt or CarboPt). After incubation periods of 24 h (A) or 48 h (B) the activation status of selected factors of the DNA damage
responsewas analyzed byWestern blot analysis using a panel of phospho-speciﬁc antibodies as indicated. For protein loading control, the expression of ERK2, GAPDH and β-actin protein
was investigated. The data are summarized in Table 2. Con, untreated control.
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and platinating drug-induced mRNA expression of susceptibility factors
Mechanisms of apoptosis, DNA repair and transport are of particular
relevance for the killing response of tumor cells to CisPt [9]. Hypothesiz-
ing that such factors might also determine the susceptibility of
normal kidney cells to platinum damage, we analyzed the mRNA ex-
pression of selected factors involved in apoptosis (Bax, Bcl-2, Xiap),
DNA repair (Csb, Ercc1, Xpa, Xpg) and transport (Ctr1, Mrp2) under
basal situation and 24 h after platinum treatment. Glomerular cells
differ from tubular cells by a higher mRNA expression of pro-
apoptotic Bax and the NER factors Xpa and Xpg (Fig. 7A). Following
treatment with platinating drugs, both RGE and NRK-52E responded
with further increase in Bax mRNA levels (Fig. 7B, C). Notably yet,
whereas NRK-52E cells largely upregulate the mRNA expression of
the NER factor Ercc1 following treatment with CisPt and OxaliPt,
but not CarboPt, this response was not observed in RGE cellsTable 2
Platinum-induced DDR of rat tubular (NRK-52E) and glomerular (RGE) cells.
Activation of mechanisms of the DDR following treatment of rat tubular (NRK-52E) and glomer
Figs. 5 and 6).−: no effect; 0: weak effect; +: moderate effect; ++: strong effect; +++: ver
Readout NRK-52E
8 h 8 h + 24 h 24 h
p-p53 CisPt ++ ++ +++
OxaliPt ++ ++ +++
CarboPt − + 0
p-Chk1 CisPt ++ + +
OxaliPt + − 0
CarboPt 0 0 ++
p-Chk2 CisPt − ++ ++
OxaliPt − ++ +
CarboPt − +++ +
p-RPA32 CisPt − ++ +
OxaliPt − + −
CarboPt − + −
p-Kap-1 CisPt 0 + ++
OxaliPt − + +
CarboPt − + ++
γH2AX CisPt + +++ ++
OxaliPt 0 ++ 0
CarboPt 0 0 −(Fig. 7B and C). RGE cells predominantly responded to CisPt and
OxaliPt with elevated mRNA levels of the transporter Ctr1 (Fig. 7C).
The data show that tubular and glomerular cells distinguish from
each other by the expression of a different spectrum of platinum-
related susceptibility factors.
3.6. Formation and repair of platinum-induced DNA adducts in tubular and
glomerular cells
To ﬁgure out whether the uptake of platinating drugs is different in
NRK-52E and RGE cells cellular platination was measured by mass
spectometry-based method. As analyzed 4 h after treatment with the
corresponding IC80, the highest level of platination was achieved by
CarboPt, in both NRK-52E and RGE cells (Fig. 8A). The lowest level of
cellular platination was found after CisPt treatment (Fig. 8A). Pt-(GpG)
intrastrand crosslinks are believed to be most relevant cytotoxic DNA
adducts formed by platinating compounds [18]. Therefore, this DNAular (RGE) cells with equitoxic doses (IC80) of CisPt, OxaliPt and CarboPt (original data see
y strong effect as compared to untreated controls.
RGE
48 h 8 h 8 h + 24 h 24 h 48 h
− 0 + − +
− 0 + − +
0 − + − +
− + ++ + −
− 0 ++ + +
+ − ++ − ++
0 0 ++ ++ 0
0 0 + + 0
++ − ++ − +
− − + + +
− − 0 0 0
+ − − 0 0
0− 0 ++ ++ ++
0 0 + 0 ++
++ − 0 0 ++
+ − ++ ++ +
++ − + ++ +
++ − 0 ++ +
Fig. 7. Comparative analysis of basal and platinum-induced mRNA expression of factors related to resistance to platinating drugs. NRK-52E and RGE cells were left untreated or were
treated with the corresponding IC80 of CisPt, OxaliPt or CarboPt. 24 h later, the mRNA expression of a subset of factors that have been linked to the CisPt sensitivity of tumor cells [17]
was analyzed by quantitative real-time PCR. Data shown are the mean ± SD from two independent experiments each performed in duplicate. Only changes in mRNA expression of
N2.0 or b0.5 (marked by dashed lines) are considered as biologically relevant. A: Cell type-speciﬁc differences in the basal expression of factors related to the regulation of apoptosis,
DNA repair and transportwere analyzed. RelativemRNA levels in RGE cells were related to that of NRK-52E cells whichwas set to 1.0. B, C: Alterations inmRNA levels following treatment
of NRK-52E (A) or RGE (B) cells with different platinum compounds. Relative mRNA expression in corresponding untreated cells was set to 1.0.
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method using Pt-(GpG)-speciﬁc antibody [53,58]. OxaliPt-induced
DNA intrastrand crosslinks are not detectable by this antibody and,
hence, were not subject to our analyses. The amount of Pt-(GpG)
crosslinks following CisPt treatment was clearly higher than after
CarboPt treatment, both in NRK52E (Fig. 8B and Supplementary
Fig. S5A) and RGE (Fig. 8C and Supplementary Fig. S5B) cells. Based on
the data we suggest that, after uptake into kidney cells, CisPt forms
Pt-(GpG) intrastrand crosslinks with a faster kinetic than CarboPt
does. Thus, although the uptake of CarboPt is not impaired as compared
to CisPt, the formation of ultimate genotoxic and cytotoxic DNAadducts,
such as Pt-(GpG) intrastrand crosslinks, occurs faster with CisPt. DNA
repair is amajormechanism that counteracts the geno- and cytotoxicity
of platinum-inducedDNA adducts [9,18]. Therefore, we investigated the
repair of CisPt- and CarboPt-induced Pt-(GpG) crosslinks in NRK-52E
and RGE cells by Southwestern analyses. Here, the decrease in Pt-
(GpG) crosslinks over time is indicative of the repair of these adducts.
The level of CisPt- and CarboPt-induced Pt-(GpG) crosslinks decreased
with time in both cell types (Fig. 8B, C), showing ongoing DNA repair
(Fig. 8D). The level of residual Pt-(GpG) crosslinks observed 72 h
after treatment was lower in RGE than in NRK-52E cells (Fig. 8B, C),
indicating that glomerular endothelial cells repair platinum-induced
intrastrand crosslinks more efﬁciently than tubular epithelial cells
(Fig. 8D). It should be noted, that this was only due for the treat-
mentwith equitoxic platinum concentrations. Using equimolar concen-
trations of CisPt a slightly reduced repair capacity of RGE cells
in comparison to NRK-52E cells was observed after post-incubation pe-
riod of 48 h (Supplementary Fig. S6).4. Discussion
In the present study we performed extensive analysis in order to
(i) elucidate the response of different types of normal rat kidney cells
(i.e. tubular epithelial cells (NRK-52E) versus glomerular endothelial
cells (RGE)) to CisPt treatment and (ii) characterize renal stress
responses elicited by various types of clincally relevant platinating
drugs (i.e. CisPt, OxaliPt, CarboPt). Calculation of IC50 and IC80 shows
that both types of kidney cells are particularly vulnerable to CisPt treat-
ment. This is in line with the fact that nephrotoxicity is the clinically
most relevant adverse effect of CisPt-based anticancer therapy [29,30].
It is hypothesized that tubular cells are the major target for CisPt-
induced DNA damage induction and cytotoxicity [29]. However, a
previous report discussed the possible involvement of glomerular
damage in the pathophysiology of acute and chronic nephrotoxicity
following CisPt treatment [47]. In linewith this, our in vitro data showed
that glomerular cells are more sensitive to CisPt than tubular cells.
Future in vivo studies are required to elucidate the in vivo relevance of
CisPt-induced glomerular damage especially for chronic nephrotoxicity
resulting from CisPt-based anticancer therapy. As RGE cells were found
to be alsomore sensitive to OxaliPt and CarboPt thanNRK-52E cells, one
might speculate that glomerular endothelial cells are in general more
sensitive to platinum-induced injury than tubular epithelial cells. How-
ever, this holds true for the in vitro situation only, as analyzed in this
study. In vivo, tubular epithelial cells have been clearly identiﬁed as
major target of CisPt induced kidney damage [29,35,47]. The contribu-
tion of glomerular damage is unclear [47]. Basically, different glomeru-
lar cell types might be affected in their function by CisPt. Apart from
Fig. 8. Formation and repair of DNA intrastrand crosslinks by platinating drugs. A: NRK-52E and RGE cellswere incubatedwith the IC80 of platinumcompounds (CisPt, OxaliPt, CarboPt) for
4 h. Afterwards, cellular platinum(Pt) contentwasmeasured bymass spectrometry as described inmethods. Data shown are themean±SDobtained froma single experiment performed
in triplicate. B, C: NRK-52E (B) and RGE (C) cells were incubated with the IC80 of CisPt or CarboPt for 4 h followed by a post-incubation period of up to 72 h in the absence of the platinum
compound. The amount of Pt-(GpG) intrastrand crosslinkswasdeterminedby Southwestern analysis using anti-(GpG)-speciﬁc antibody as described inmethods. Autoradiographieswere
analyzed densitometrically and the signal intensitiy of the untreated controlswas substracted. Shown are themean±SD from two independent experiments each performed in duplicate.
D: NRK-52E and RGE cellswere incubatedwith the IC80 of CisPt for 4 h followed by a post-incubation period of up to 72 h in the absence of the platinum compound. The amount of residual
Pt-(GpG) intrastrand crosslinks was determined by Southwestern analysis as described in methods. Shown are the mean ± SD from 3 independent experiments each performed in du-
plicate. **p ≤ 0.01.
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particular relevance for chronic kidney disease, endothelial cells
are exposed to the highest concentration of drugs due to their barrier
function. Hence, it is tempting to speculate that persisting glomerular
endothelial damage following platinum treatment might promote
glomerular endothelial dysfunction, which could promote chronic
kidney dysfunction. Forthcoming in vivo studies are preferential to
experimentally address this question. Notably, as compared to CisPt
and OxaliPt, cytotoxicity evoked by CarboPt occured with a delay of
about 16–24 h (see Fig. 1). The molecular reason for this is unclear.
Results obtained from the analysis of cellular platination and the forma-
tion of Pt-(GpG) intrastrand crosslinks indicate that the delayed onset of
CarboPt toxicity is independent of drug uptake mechanisms. Rather it
might be due to a delayed formation of cytotoxic DNA adducts, which
is in line with a report showing that the formation of CarboPt DNA
adducts is slow as compared to CisPt [59]. It is also known that thespectra of DNA intrastrand crosslinks generated by CisPt or CarboPt
treatment signiﬁcantly differ from each other. In vitro studies showed
that CisPt forms approximately 65% 1,2-(GpG), 25% 1,2-(ApG) and 5–
10% 1,3-(GpNpG) intrastrand crosslinks [18,60]. While OxaliPt shows
a similar spectrum of the DNA-adducts as CisPt [61,62], CarboPt
treatment results in a largely different spectrum of DNA intrastrand ad-
ducts, with 1,3-(GpNpG) intrastrand adducts being the main type of
DNA adduct (36%), followed by ~30% of 1,2-(GpG) and ~15% of 1,2-
(ApG) intrastrand adducts [15,59]. Hence, it is feasible that the deceler-
ated kinetics of cytotoxicity resulting from CarboPt treatment is related
to qualitative and quantitative characteristics in DNA adduct formation.
Based on these results, we hypothesized that the preferential neph-
rotoxicity of CisPt might result from speciﬁc type(s) of CisPt-induced
DNA adducts and subsequent speciﬁc damage responses. In order to
identify speciﬁc renal stress responses that are triggered by CisPt
but not by other types of platinum compounds, we used equitoxic
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deﬁned by the viability measured 72 h after drug addition) for further
analyses instead of equimolar doses as done in most published studies.
This experimental setting facilitates an assessment of the contribution
of different molecular mechanisms for total cytotoxicity as reﬂected
by a decrease in cell viability. Data obtained from cell cycle analyses of
platinum-treated NRK-52E cells supported the viability data, showing
that CisPt is the most cytotoxic drug, as it increases the fraction of
(apoptotic) SubG1 cells already 24 h after treatment with the IC50.
Moreover, these analyses conﬁrmed the delayed toxicity resulting
from exposure to CarboPt. Intriguingly, as opposed to tubular cells,
treatment of glomerular cells with equitoxic doses of the platinating
drugs failed to increase the number of cells present in SubG1 fraction.
Rather, glomerular cells accumulated in G2/M phase of the cell cylce
following platinum treatment, showing that signiﬁcant qualitative
differences exist in the stress response evoked by platinum injury in
tubular and glomerular cells. While tubular cells preferentially undergo
apoptosis if exposed to platinating agents, glomerular cells predomi-
nantly respond with a disturbed cell cycle progression. To further
dissect the effects of different platinum compounds on cell cycle-
related mechanisms, the mitotic index was determined. As analyzed
24 h after exposure to IC80, OxaliPt was most efﬁcient in decreasing
mitotic index, as reﬂected by a reduced number of p-H3 positive NRK-
52E and RGE cells. This data points to agent-speciﬁc differences in the
activation of cell cycle checkpoints. This view gained support by the
observation that OxaliPt was also most efﬁcient in disrupting S-phase-
related mechanisms, as indicated by a reduced EdU incorporation in
NRK-52E cells. Of note, as opposed to NRK-52E cells, RGE cells revealed
a slight increase in EdU positive cells following treatment with OxaliPt
and CarboPt, accentuating the cell type speciﬁcity of platinum-induced
stress responses.
Measuring the activation of the caspases 3 and 7, we observed the
strongest activation 24 h after treatment of NRK-52E cells with the
IC80 of CisPt and OxaliPt. At lower concentration (IC50) only CisPt was
effective in stimulating caspase activity. Analyzing the involvement of
caspase 3 and 7 separately, we found that CisPt results in cleavage of
both procaspase 3 and 7, while OxaliPt showed substantial cleavage
of procaspase 7 only. RGE cells responded to platinum treatment with
a weak stimulation of caspase activity and a moderate cleavage of
procaspases 3 and 7. This is in line with the ﬂow cytometry-based
data showing that initiation of apoptosis by platinating compounds
is prior to tubular cells. Of note, IC50 and IC80 of CarboPt induced a
moderate increase in the level of cleaved procaspase 7 selectively in
glomerular but not in tubular cells, re-emphasizing the observation that
tubular cells fundamentally distinguish from glomerular cells regarding
the molecular mechanims underlying platinum-induced toxicity.
Induction of DNA damage is a major trigger of cell death following
exposure to conventional anticancer drugs. Therefore, we thoroughly
investigated the inﬂuence of platinating drugs on the (i) formation of
DSBs by monitoring the formation of nuclear γH2AX foci formation as
surrogate marker of DSBs and (ii) the activation of the DDR by mea-
suring ATM/ATR-catalyzed phosphorylation reactions using phospho-
speciﬁc antibodies. While tubular and glomerular cells similarly
responded to ionizing radiation, exposure to platinating drugs stimulat-
ed complex cell type- and agent-speciﬁc responses. The formation of
DSBs occured faster and at lower platinum concentrations in glomerular
as compared to tubular cells. While NRK-52E cells showed a dose de-
pendent response 24 h after platinum treatment, the RGE cells reached
their maximum damage response already at the IC50. These ﬁndings are
in line with the lower IC50 and IC80 found in RGE cells. Although
glomerular cells are particularly susceptible to the formation of DSBs fol-
lowing platinum treatment, they do not undergo apoptosis as might
have been anticipated [63]. Rather, glomerular cells preferentially
activate checkpoint control mechanisms as concluded from the ﬂow
cytometry data and assaying the activation of checkpoint kinases (see
below).The effects of the different platinum compounds on mechanisms of
the DDR are rather complex and both agent- and cell type-speciﬁc
(Table 2). Regarding the aspect of cell type speciﬁcity it is noticeable
that activation of p53 is rather effective in tubular as compared to
glomerular cells. Tubular cells also reveal high levels of p-Chk2 and
p-Kap1. Glomerular cells are characterized by a substantial increase in
p-Chk1 and p-Chk2 levels, which is indicative of highly efﬁcient
activation of checkpoint controlmechanisms.With regard to the agents,
CisPt is in general most effective in stimulating multiple DDR mecha-
nisms in both cell types. This might be an explanation for its particular
nephrotoxicity. Due to its late onset of cytotoxicity CarboPt differs
from the other platinum compounds and, hence, this drug is of particu-
lar interest. CarboPt is very effective in stimulating Chk2, but not of
Chk1, in tubular cells and strongly triggers phosphorylation of both
Chk1 and Chk2 in glomerular cells. Recently, ATR-Chk2 signaling has
been suggested to be particularly relevant for CisPt-induced apoptosis
in renal cells [37]. In line with this study, we found an efﬁcient stimula-
tion of ATR-Chk2 signaling by CisPt, OxaliPt and CarboPt in tubular and
glomerular cells. Phosphorylation of the chromatin-associated protein
Kap-1 following CarboPt treatment is preferential in tubular cells.
Notably, Kap-1 phosphorylation triggered by CisPt andOxaliPt is similar
in both renal cell types. This is indicative of different accessibility of
chromatin for repair factors if tubular and glomerular cells are exposed
to CarboPt. One possible explanation for the speciﬁc effects of CarboPt
on DDR is that, upon uptake into the cell, qualitatively different types
of DNA adducts are formed (and processed) with time, which elicit a
different subset of DDR mechanisms. It is feasible that the complex
responses to platinum-induced DNAdamage are related tomechanisms
of recognition of the primary DNA adduct. For instance, DNA mismatch
repair (MMR) proteins are important for the recognition of CisPt
adducts and subsequent activation of c-Jun-N-terminal kinase (JNK)
and c-Abl kinases in response to CisPt damage but not in response to
OxaliPt adducts [28]. Forthcoming studies are necessary to elucidate
the nature of the primary or secondary DNA damage induced by the
different types of platinum drugs, which eventually favor the
activation of speciﬁc branches of the DDR.
DNA repair is a major mechanism that counteracts the geno- and
cytotoxicity of platinum-induced DNA adducts. For instance, the repair
protein ERCC1, which is involved in the repair of DNA intrastrand
crosslinks by NER [64], is a key factor determining the sensitivity of
tumor cells to CisPt [17]. Moreover, DNA repair has also been suggested
to interfere with peripheral neuropathy following CisPt treatment [34].
RGE cells were characterized by a higher basal expression level of
NER factors as compared toNRK-52E. In linewith this, glomerular endo-
thelial cells revealed a faster repair kinetic of Pt-(GpG) intrastrand
crosslinks than tubular epithelial cells if treated with equitoxic concen-
trations. It should be noted that treatment of NRK-52E and RGE cells
with equimolar concentrations of CisPt showed a different result.
Under this experimental setting, RGE cells revealed slightly reduced
removal of CisPt adducts as compared to NRK-52E cells. Despite their
efﬁcient NER capacity, RGE cells are unexpectedly sensitive to
platinating drugs as judged from the IC50 and IC80. This phenomenon
is likely not due to the higher expression level of pro-apoptotic Bax in
RGE cells, because induction of apoptosis, as reﬂected on the levels of
SubG1 fraction and caspase activity, is quite weak in RGE as compared
to NRK-52E (see Fig. 3 and Fig. 5). Rather, efﬁcient activation of check-
point mechanisms, notably in G2/M phase of the cell cycle, seems to
account for the high sensitivity of glomerular endothelial cells to
platinum damage. Following CisPt and OxaliPt treatment, NRK-52E
cells responded with a substantial increase in Ercc1 expression, which
is indicative of activation of NER. Such adaptive response was not
observed in RGE. Rather, RGE showed upregulation of the copper
transporter Ctr1. As Ctr1 is involved in drug import [3,65,66], this
stress response of RGE can be interpreted as a toxicity promoting
effect of platinating drugs. Notably, neither Ercc1 nor Ctr1 expression
was upregulated by CarboPt, again highlighting the fact that the
697K. Krüger et al. / Biochimica et Biophysica Acta 1853 (2015) 685–698activation of inducible stress responses depends on the type of
platinating agent.
Summarizing, based on our in vitro data we suggest that, apart
from damage of tubular epithelial cells, injury of glomerular endothelial
cells might also contribute to nephrotoxicity resulting from CisPt-based
anticancer therapy. Effective activation of multiple mechanisms of the
DDR by CisPt is indicative of its extraordinary high cytotoxic potential
on renal cells. While tubular epithelial cells prefentially undergo apo-
ptosis following exposure to equitoxic doses of platinumdrugs, glomer-
ular endothelial cells are characterized by a profound activation of
checkpoint control mechanisms leading to cell cycle arrest and a fast re-
pair of Pt-(GpG) intrastrand crosslinks. Mechanisms of the DDR activat-
ed by the various platinum compounds are unforeseeable complex,
reﬂecting high agent- and cell type-speciﬁcity. Out of the different plat-
inum compounds CarboPt is characterized by a late onset of cytotoxici-
ty, which is likely related to kinetic differences in the formation of
ultimately cytotoxic primary and secondary DNA adducts, which are
structurally different from adducts formated by CisPt or OxaliPt.
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